Breast Cancer Treatments and Fertility Options for Indian Women

Fertility preservation methods available in India

Fertility preservation options available in India include egg freezing, also known as oocyte cryopreservation, and embryo freezing. These are among the most effective methods and should ideally be completed before starting cancer treatment.

Chharitha Veerapaneni, who grew up in the Detroit metro area, is an Ob/Gyn at Austin Regional Clinic. Her medical practice focuses on reproductive health, fertility, childbirth, and menopause.

Addressing societal and emotional pressures

Fertility concerns are closely linked to emotional wellbeing, relationships, and social expectations in India. Marriage, family pressure, and societal perceptions add stress to a cancer diagnosis, meaning patients need medical guidance as well as psychological support and counseling.

Before her tenure at the University of Mississippi Medical Center, Eifling worked for two years in a NICU located in Monroe, Louisiana. Lacey Nelson is the social work manager at the University of Mississippi Medical Center.

Dr. Mary Taylor is the CEO and Suzan B. Thames Chair of Children’s of Mississippi. Eifling’s sister received medical care at the University of Mississippi Medical Center for Type 1 diabetes.

Early detection and diagnostic protocols

Early detection of breast cancer improves long-term survival chances and makes treatment less complicated. Under India’s public-health framework, trained providers offer periodic clinical breast examinations to women aged 30 years and above.

The specific starting age and frequency for these screenings depend on a person's age, risk factors, family history, and established medical guidelines.

If clinical or imaging findings appear suspicious, doctors usually perform a core needle biopsy. Early diagnosis can allow for breast-conserving surgery instead of removing the entire breast.

Personalized surgical and medical treatment plans

Modern oncology personalizes breast cancer treatment based on tumor size, stage, grade, lymph-node involvement, and hormone-receptor status.

Treatment aims to achieve safe cancer control using the least invasive surgery necessary rather than the largest possible operation. A patient may undergo breast-conserving surgery, known as a lumpectomy, which removes only the tumor and a small margin. Alternatively, a mastectomy involves removing the whole breast, depending on tumor size, location, breast size, genetic risk, treatment response, and patient preference.

Sentinel lymph-node biopsy examines the first few lymph nodes likely to receive cancer cells.

It may be given before surgery, known as neoadjuvant therapy, to shrink a large tumor and potentially make breast-conserving surgery possible.

Sami Mansfield argued on 8 November 2026 that a GLP-1 prescription is not a complete survivorship plan because it fails to coordinate oncology follow-up, strength training, or nutritional support. A 2025 joint advisory from groups including the American College of Lifestyle Medicine and the American Society for Nutrition recommends that patients receiving GLP-1 treatment undergo assessments of strength and function. These patients also require adequate nutrition and resistance training.

The American Society of Clinical Oncology (ASCO) recommends that patients undergoing active treatment with curative intent participate in both aerobic and resistance exercise, according to their 2022 guideline. Mansfield suggested that oncology follow-up visits should include routine inquiries about weight management medications and assessments of daily function like grip-strength or chair-rise tests. These visits should also include referrals to dietitians and exercise professionals familiar with oncology.

Weight loss should not be the only measure of success, as lean mass and skeletal muscle are not interchangeable. Body composition scans do not automatically confirm lost strength or drug-induced frailty. Mansfield emphasized that medication discontinuation should be managed as a clinical issue rather than an administrative detail. Factors such as cost, insurance coverage changes, and side effects often cause patients to stop treatment.

A 2022 study by Wilding JPH et al. published in Diabetes, Obesity and Metabolism analyzed weight regain and cardiometabolic effects after the withdrawal of semaglutide in the STEP 1 trial extension.

Debunking common breast cancer myths

The absence of pain does not mean a lump is harmless.

Breast pain is rarely the first sign of cancer, as it is usually caused by hormonal changes, infections, or medications. Persistent pain with a lump, skin, or nipple change should be evaluated by a professional.

Common myths that delay diagnosis include beliefs that every patient needs total breast removal or that chemotherapy is required for everyone. Other misconceptions suggest cancer treatment is always unsuccessful, even though these beliefs can delay necessary care.

Risk factors and screening awareness

Having risk factors does not guarantee cancer, and lacking them does not guarantee safety. While breast cancer is most common in women, approximately 0.5–1% of cases occur in men.

Breast self-awareness is useful, but it does not replace the need for clinical examinations or mammography when recommended. This includes women with a very high lifetime risk or those with certain genetic mutations.